about the author

Endpoints Contributor

help@endpts.com

author articles

Vi­da Ven­tures: Pow­er­ing Break­throughs in Bio­phar­ma

5 years ago

Re­vis­it­ing the 'cy­tokine stor­m' in ARDS; the painful wait for an­ti-in­flam­ma­to­ry drugs/tar­gets that solve Covid-19 ...

5 years ago
Biotech Voices

Da­ta Lit­er­a­cy: The Foun­da­tion for Mod­ern Tri­al Ex­e­cu­tion

5 years ago

We’re poised for a new era of med­ical ad­vances. A key step: un­der­stand­ing the mol­e­c­u­lar ma­chines that gov­ern health ...

5 years ago
Biotech Voices

5AM Ven­tures: Fu­el­ing the Next Gen­er­a­tion of In­no­va­tors

5 years ago

Next-gen ther­a­pies are evolv­ing fast. The drug de­vel­op­ment mod­el needs to keep up

5 years ago
Biotech Voices

I-Mab —A Biotech on the Rise with In­spired Sci­ence

5 years ago

Fos­ter­ing Re­silien­cy at the Cross­roads of Try­ing Times: A Tool­box for Em­ploy­ee Agili­ty

5 years ago

Bio­science in­dus­try stake­hold­er col­lab­o­ra­tion key to ad­dress­ing in­equal­i­ty

5 years ago
Biotech Voices

Hair­pins and Scis­sors - De­liv­er­ing a Non-Gene Edit­ed Al­lo­gene­ic CAR T Cell Ther­a­py for the Mass­es

5 years ago

Putting Da­ta to Work in a Pan­dem­ic

5 years ago

Clin­i­cal tri­al mon­i­tor­ing is about to change for­ev­er

5 years ago

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

5 years ago

Biotech IPOs: New Steps to Suc­cess on the Road to Go­ing Pub­lic

5 years ago

Evolv­ing Treat­ment Land­scape for NASH

5 years ago

How In­no­v­a­tive Tech­nolo­gies and a Ded­i­cat­ed Site Net­work is Dri­ving Pa­tient Re­cruit­ment for Biotech Clin­i­cal Tri­als ...

5 years ago

A new chap­ter in the de­cen­tral­ized clin­i­cal tri­al ap­proach

5 years ago

Solv­ing Phar­ma’s Da­ta Si­lo Prob­lem: Why a Link­able Da­ta In­fra­struc­ture is Good for Bio­phar­ma and Good for Pa­tients

5 years ago

How Clini­cReady by Aus­tralian CRO Avance Clin­i­cal de­liv­ers pre­clin­i­cal project man­age­ment and sci­en­tif­ic and ...

5 years ago

Mi­no­ryx and Sper­o­genix ink an ex­clu­sive li­cense agree­ment to de­vel­op and com­mer­cial­ize lerigli­ta­zone in Chi­na

5 years ago

Five Steps to Guide Suc­cess­ful Risk-Based De­cen­tral­ized Clin­i­cal Tri­als

5 years ago

Open & Flex­i­ble Tech­nol­o­gy Can En­able Break­through In­no­va­tion

5 years ago

The In­ge­nu­ity En­gine: Trans­la­tion­al Re­search and the Need for Speed

5 years ago

FSP and COVID-19: Im­pact on Clin­i­cal Tri­al De­vel­op­ment

5 years ago
First page Previous page 567891011 Next page Last page
A service from the Financial Times